

(19) Japanese Patent Office (JP)

(11) Unexamined Patent  
Application (Kokai) No.

**(12) Unexamined Patent Gazette (A)**

**56-122328**

(51) Int. Cl. <sup>3</sup>	Classification Symbols	Internal Office Registration Nos.	(43) Date of Publication: September 25, 1981
C 07 C 59/46		7188-4C	
		7188-4C	
A 61 K 31/557	AEL	6617-4C	
C 07 C 177/00		7430-4H	

Request for Examination: Not yet submitted      Number of Claims: 2      Total of 4 pages [in original]

---

(54) Title of the Invention:      CRYSTALLINE AMINE SALT OF  
METHANOPROSTACYCLIN DERIVATIVE,  
MANUFACTURING METHOD THEREOF, AND  
PURIFYING METHOD THEREOF

(21) Application No.:      55-25726

(22) Date of Filing:      February 29, 1980

(72) Inventor:      Kawakami, Hajime  
Takarazuka-shi, Hyōgo-ken 2-chome, 14-ban, 7-go

(72) Inventor:      Ono, Keiichi  
Osaka-shi, Higashiyodogawa-ku, Higashiawaji 1-chome, 5-ban, 3-530-go

(72) Inventor:      Sugie, Akihiko  
Toyonaka-shi, Sonehigashinocho, 2-chome, 10-ban, 1-116-go

(72) Inventor:      Katsube, Sumimoto  
Toyonaka-shi, Machiganeyama-cho, 10-20

(71) Applicant:      Sumitomo Chemical Co., Ltd.  
Osaka-shi, Higashi-ku, Kitahama, 5-chome, 15-banchi

(74) Agent:      Katsuya Kimura, Patent Attorney


SPECIFICATION

**1. Title of the Invention**


CRYSTALLINE AMINE SALT OF METHANOPROSTACYCLIN DERIVATIVE,  
MANUFACTURING METHOD THEREOF, AND PURIFYING METHOD THEREOF

## 2. Claims

(1) A dicyclohexylamine salt of a methanoprostacyclin derivative expressed by the general formula




(where R<sup>1</sup> is a trityloxymethyl group, 3-trityloxy-*trans*-1-propenyl group, or the group expressed by the general formula




(where R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are each a hydrogen atom or a methyl group)).


(2) A method for manufacturing a dicyclohexylamine salt of a methanoprostacyclin derivative expressed by the general formula



(where R<sup>1</sup> is a trityloxy group, 3-trityloxy-*trans*-1-propenyl group, or a group expressed by the general formula



(where R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are each a hydrogen atom or a methyl group)), characterized in that a mixture of a methanoprostacyclin derivative expressed by the general formula




(where R<sup>1</sup> is the same as above) and a 7-Z isomer thereof is converted to a crystalline salt by dicyclohexylamine and is further recrystallized as needed.

### 3. Detailed Description of the Invention

#### (Field of Industrial Utilization)

The present invention relates to a crystalline dicyclohexylamine salt of a methanoprostacyclin derivative, a manufacturing method thereof, and a purifying method thereof.

Methanoprostacyclin [II] was discovered as a stable derivative of prostacyclin (PGI<sub>2</sub>), a natural bioactive substance having a strong blood platelet coagulation-inhibiting action (Tetrahedron Letters, 2607 (1979)). Methanoprostacyclin [II] is by far more chemically stable than prostacyclin, has the same strong blood platelet coagulation-inhibiting action as PGI<sub>2</sub>, and is an extremely useful compound in the treatment of arteriosclerosis, heart failure, thrombosis, and the like. Total synthesis of methanoprostacyclin and derivatives thereof has been reported by the inventors and several other groups of researchers, but all the reported methods use a Wittig reaction between a ketone derivative [III] and an ylide derivative [IV], as shown below.



This reaction has an excellent yield but has a serious drawback of typically producing an unnecessary 7Z isomer [II'] as a byproduct (the generation rate is [II]:[II'] = 7:2, *Tetrahedron Letters*, 433 (1979)). In addition, the properties of the two are extremely similar (R<sub>f</sub> value is 0.14 for 7E, and 0.17 for 7Z; *Tetrahedron Letters*, 433 (1979)), making separation and purification very difficult. Also, the melting point of this compound is fairly low (68°C to 69°C, *Tetrahedron Letters*, 3743 (1978)), and crystallization is therefore severely impeded by the admixing of trace impurities.


On the other hand, the 7Z isomer [II'] has an extremely low pharmacological activity compared with methanoprostacyclin [II]. For example, the blood platelet coagulation-inhibiting action of II' is about 1/100 of II (*Tetrahedron Letters*, 433 (1979)).

Thus, establishment of an efficient and industrially viable method of separating isomers of methanoprostacyclin derivatives is essential in the development of these derivatives as pharmaceutical products.


In view of the above, the inventors conducted an examination of various separation and purification methods after achieving success in the synthesis of methanoprostacyclin, and finally succeeded in inventing an extremely simple and industrially viable purification method. The present invention relates to this novel purifying method and to a novel dicyclohexylamine salt of a methanoprostacyclin derivative [I] obtained thereby.

The methanoprostacyclin derivative in which any of R<sup>2</sup>, R<sup>3</sup>, or R<sup>4</sup> in general formula [I] is a methyl group has excellent blood platelet coagulation-inhibiting action in the same manner as methanoprostacyclin (Japanese Laid-open Patent Application No. 54-119444), and a methanoprostacyclin derivative in which R<sup>1</sup> is a trityloxymethyl group or a 3-trityloxy-*trans*-1-propenyl group is important as an intermediate of methanoprostacyclin synthesis (Japanese Patent Application Nos. 54-29233 and 54-29236).

According to the present invention, a dicyclohexylamine salt of a methanoprostacyclin derivative expressed as methanoprostacyclin derivative [I]



(where R<sup>1</sup> is a trityloxymethyl group, 3-trityloxy-*trans*-1-propenyl group, or the group expressed by the general formula



(where R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are each a hydrogen atom or a methyl group))

can be obtained in the following manner. Specifically, the dicyclohexylamine salt is obtained by mixing a methanoprostacyclin derivative [I] or a methanoprostacyclin derivative [I] containing the corresponding 7Z isomer [I']

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.